3rd Epigenetics in Drug Discovery
Conference - Boston, Massachusetts, United States
GTC’s 3rd Epigenetics in Drug Discovery conference is the only epigenetics conference that brings together a balanced mix of leading experts from the industry and academia to collaborate on the latest cutting edge research on novel epigenetic mechanisms, therapeutics, developments, biomarkers and diagnostics. Venture Capitalists will also join the conference to discuss investment opportunities and what they look for in the epigenetics space.
Some key discussions around epigenetics drug discovery at the conference include: 1) The role of epigenetics in human diseases such as cancer, leukaemia, neurodegenerative conditions, neuropsychiatric disorders, inflammation, etc. 2) Novel mechanisms, biomarkers, technologies and diagnostics for epigenetics drug discovery 3) Cutting edge research from GlaxoSmithKline, Epizyme, Genentech, Constellation, Astex, Cellzome, RaNA Therapeutics, Pfizer, Harvard, Massachusetts Institute of Technology, etc.
Conference sessions are:
Epigenetic Mechanisms
Role of Epigenetics in Human Diseases
Drug Discovery in Epigenetics
Preclinical and Clinical Development
Epigenetic Biomarkers and Diagnostics
Panel Discussion: Investment Opportunities in the Epigenetic Space
(Courtesy of Epigenetics R&D Pipeline - Histone Deacetylases (HDACs), via asdreports.com)
3rd Epigenetics in Drug Discovery
May 8-10, 2013
Hyatt Regency, 1 Ave De Lafayette, Boston, Massachusetts, US
If you'd like to ask a question or post a comment about this talk please do so below.
This seminar posting is brought to you by Biotechnology Calendar, Inc. providing access to research information and research tools for nearly 20 years. Visit our Science Market Update Blog for current science funding and market information or see our schedule of upcoming science research laboratory product shows.
